Skip to main content

Table 1 Clinical characteristics of study population

From: Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

VariablesTicagrelor 90 mg (n = 171)Ticagrelor 60 mg (n = 178)Clopidogrel 75 mg (n = 176)P-value
Age (years)63.5 ± 7.465.3 ± 8.264.9 ± 7.10.469
Gender (female), n(%)62 (36.3%)68 (38.2%)67 (40.3%)0.741
Body mass index (Kg/m2)23.8 ± 3.423.5 ± 3.824.2 ± 3.90.869
Diabetes Mellitus, n(%)52 (30.4%)58 (32.6%)56 (31.8%)0.910
Hypertension, n(%)92 (53.8%)85 (47.8%)82 (46.6%)0.363
Current smoker, n(%)69 (40.4%)75 (42.1%)72 (40.9%)0.937
Previous MI, n(%)82 (48.0%)80 (44.9%)78 (44.3%)0.772
Previous ischemic CVA, n(%)39 (22.8%)45 (25.3%)38 (21.6%)0.710
Previous GI bleeding, n(%)7 (4.1%)8 (4.5%)5 (2.8%)0.716
Peptic Ulcer, n(%)21 (12.3%)25 (14.0%)24 (13.6%)0.886
LVEF(%)43.2 ± 5.544.4 ± 6.743.9 ± 5.80.863
NYHA 2–3 on admision, n(%)115 (67.3%)109 (61.2%)112 (63.6%)0.499
eGFR, ml/min/1.73 mm264.5 ± 21.765.1 ± 21.963.9 ± 22.40.782
CRUSADE score32.1 ± 5.233.4 ± 5.532.8 ± 6.20.792
Medication
ACEI/ARB, n(%)80 (46.8%)75 (42.1%)82 (46.6%)0.622
Beta-blockers, n(%)75 (43.9%)69 (38.8%)78 (44.3%)0.515
Statin, n(%)165 (96.5%)170 (95.5%)166 (94.3%)0.634
PPI, n(%)166 (97.1%)174 (97.8%)170 (96.6%)0.807
  1. Abbreviations: MI, myocardial infarction; CVA, cerebrovascular accident; GI, gastrointestinal; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor